期刊文献+

FK506致肝功能异常2例并文献复习 被引量:4

Fk506 caused 2 cases liver damage after kidney transplantation and review of literature
原文传递
导出
摘要 目的探讨FK506的肝毒性。方法报告2例肾移植术后应用FK506后,出现转氨酶、胆红素升高。结果1例仅停药后肝功恢复;另1例经停药,保肝治疗后恢复。结论FK506可引起肝脏损害,致转氨酶、胆红素升高,临床应用中注意该项副作用。 Objective To discuss the drug - induced liver damage by FKS06. Methods Clinical data of 2 cases whose alanine aminotransferase(ALT), bilirubin (T- Bil ) elevating with oral take FKS06 after renal transplantation had been analysed. Results One patient's hepatic function had returned normal after stopping FK.506; the other had returned normal after stopping FKS06 and giving liver - protective remedies. Conclusion FKS06 may cause liver damage and liver function, so they should be monitored in renal recipients particularly.
出处 《临床医学》 CAS 2007年第11期5-7,共3页 Clinical Medicine
关键词 FK506 肝毒性 药物副作用 Tacrolimus Hepatotocxicity Adverse drug reactions
  • 相关文献

参考文献8

二级参考文献26

  • 1薛武军,陈勇,邢俊平,田普训.高危患者肾移植体会[J].中华泌尿外科杂志,1996,17(7):402-404. 被引量:3
  • 2Pirsch JD, Miller J, Deierhoi MH. A comparison of taerolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.Transplantation, 1997, 63: 977-983.
  • 3Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantaion,2002, 73: 775-782.
  • 4Tanabe K, Ishikawa N, Tokumoto T, et al. Long-term results of living kidney transplantaion under tacrolimus immunosuppression: a single-centre experience. Transplant Proc, 1998, 30:1224-1226.
  • 5Cecka JM, Cho YW, Terasaki PI. Analyses of the UNOS Scientific Renal Transplant Registry at three years-early events affecting transplant success. Transplantation, 1992, 53: 59-64.
  • 6Kliem V, Petersen R, Ehlerding G, et al. Tacrollmus for steroidand OKT3-resistant rejection in kidney recipients. Transplant Proc,1998, 30: 1251-1253.
  • 7Friemann S, Feuring E, Padberg W, et al. Improvement of nephrotoxicity, hypertension, and lipid metabolis after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc,1998, 30: 1240-1242.
  • 8Mayer AD, Dmitrewski J, Squifflet JP, et al. Mulficenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the Etuopean Tacrolimus Multicenter Renal Study Group. Transplantation, 1997,.
  • 9何长民,肾脏替代治疗学,1999年,424页
  • 10薛武军 田普训 等.感染乙肝尿毒症患者肾移植的临床研究[J].中华外科杂志,2000,38(9):689-689.

共引文献266

同被引文献54

  • 1夏穗生.肝移植进展[J].中国普外基础与临床杂志,2005,12(2):97-99. 被引量:9
  • 2毕颎,陈规划,何晓顺,胡瑞德,文剑明.肝移植术后免疫抑制剂引起肝损害的病理学改变(附26例肝活检报告)[J].中华肝胆外科杂志,2006,12(5):306-308. 被引量:6
  • 3邹卫龙,臧运金,陈新国,岳扬,沈中阳.肝移植患者将他克莫司替换为环孢素A的临床分析[J].中华器官移植杂志,2006,27(11):672-674. 被引量:5
  • 4戴澄,王平,张清,陈伟星.不同免疫抑制方案对移植肾早期功能的影响[J].中国现代医学杂志,2006,16(21):3295-3297. 被引量:4
  • 5Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science, 1991,251 (4991) : 283-285.
  • 6Schreiber SL, Crabtree CR. The mechanism of action of eyclosporin A and FK506. Immunol Today, 1992,13(2) : 136.
  • 7Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Transplantation, 1996,61(5) :722-729.
  • 8Przepiorka D, Nash RA, Wingard JR, et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant, 1999,5 (2) : 94-97.
  • 9Pescovitz MD, Conti D, Dunn J, et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmaeokinetles. Clin Transplant,2000,14(3):179-188.
  • 10Kemper MJ,Spartà G,Laube GF. Neuropsychologic side-effects of tacrolimus in pediatric renal transplantation[J].Clinical Transplantation,2003,(02):130-134.doi:10.1034/j.1399-0012.2003.00028.x.

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部